Mitchell von Itzstein, M.D. - Faculty Profile

Biography

Mitchell von Itzstein, M.D., is an Assistant Professor in the Department of Internal Medicine at UT Southwestern and a member of its Division of Hematology and Oncology. His clinical interests include the treatment of lung cancer and other thoracic malignancies, and the use of immunotherapy and targeted therapy. He is dedicated to the treatment of patients with cancer and researching novel treatment approaches to improve outcomes for patients.

Dr. von Itzstein was born and raised in Queensland, Australia. He holds a bachelor's degree in pharmaceutical science and master's degree in pharmacy from Griffith University, he also earned his medical degree and was awarded the university medal for academic excellence. He completed internal medicine residency training and a medical oncology fellowship at UT Southwestern.

Dr. von Itzstein's research interests include lung cancer, immunotherapy, targeted therapy, artificial intelligence, and clinical trials. He is active in lung cancer and immunotherapy research and has published more than 40 peer-reviewed articles, most as leading author. He serves as site principal investigator on several clinical trials and has been invited to give lectures both nationally and internationally.

Dr. von Itzstein's interests outside of medicine include traveling with his wife, hiking, and following sports, including tennis, Formula One racing, and rugby.

Education

Medical School: Griffith University, Australia (2017)
Residency: UT Southwestern Medical Center (2020), Internal Medicine
Fellowship: UT Southwestern Medical Center (2024), Medical Oncology

Publications

Acknowledging and addressing real-world challenges to treating immune-related adverse events: von Itzstein MS, Gerber DE, Bermas BL, Meara A Journal for ImmunoTherapy of Cancer 2024 Jul 12
Use of artificial intelligence chatbots in clinical management of immune-related adverse events: Burnette H, Pabani A, Von Itzstein MS, Switzer B, Fan R, Ye F, Puzanov I, Naidoo J, Ascierto PA, Gerber DE, Ernstoff MS, Johnson DB Journal for ImmunoTherapy of Cancer 2024 May 12
Resistance Mechanisms in ROS1-Positive Lung Cancer: New Insight into a Rare but Clinically Important Entity: von Itzstein MS, Gerber DE Clinical chemistry 2024 Apr 70 571-573
Telemedicine and Cancer Clinical Research Opportunities for Transformation: von Itzstein MS, Gwin ME, Gupta A, Gerber DE Cancer Journal 2024 Jan 30 22-26
Distinct autoantibody profiles across checkpoint inhibitor types and toxicities: Mu-Mosley H, von Itzstein MS, Fattah F, Liu J, Zhu C, Xie Y, Wakeland EK, Park JY, Kahl BS, Diefenbach CS, Gerber DE OncoImmunology 2024 13
Highly variable timing renders immunotherapy efficacy and toxicity impractical biomarkers of one another in clinical practice: von Itzstein MS, Yang Y, Wang Y, Hsiehchen D, Sheffield TY, Fattah F, Popat V, Ahmed M, Homsi J, Dowell JE, Rashdan S, Lohrey J, Hammers HJ, Hughes RS, Wang T, Xie Y, Gerber DE Frontiers in immunology 2024 15
T-cell tolerant fraction as a predictor of immune-related adverse events: Ostmeyer J, Park JY, Von Itzstein MS, Hsiehchen D, Fattah F, Gwin M, Catalan R, Khan S, Raj P, Wakeland EK, Xie Y, Gerber DE Journal for ImmunoTherapy of Cancer 2023 Aug 11
Systemic immune parameters after prior radiation therapy in patients receiving immune checkpoint inhibitors: Mundra V, Yang Y, von Itzstein MS, Fattah F, Gonugunta AS, Hannan R, Pop LM, Zhang Y, Wang Y, Sheffield T, Xie Y, Dowell JE, Homsi J, Rashdan S, Park J, Li Q, Wakeland EK, Gerber DE Translational Oncology 2023 Aug 34
Quantitation of cardiac troponin i in cancer patients treated with immune checkpoint inhibitors: A case-control study: Ulndreaj A, Brinc D, Altan M, Pons-Belda OD, Fernandez-Uriarte A, Mu-Mosley H, Fattah F, Von Itzstein MS, Soosaipillai A, Kulasingam V, Palaskas NL, Gerber DE, Diamandis EP, Heymach JV, Prassas I Clinical Chemistry and Laboratory Medicine 2023 Jan 61 154-161
Antibiotic Prescriptions in Lung Cancer and Melanoma Populations: Differences With Potential Clinical Implications in the Immunotherapy Era: Gonugunta AS, Von Itzstein MS, Hsiehchen D, Le T, Rashdan S, Yang H, Selby C, Alvarez C, Gerber DE Clinical lung cancer 2023 Jan 24 11-17

Honors & Awards

Best of the Best Clinical Research Presentation
Clinical Oncology Society of Australia Annual Scientific Meeting (2021)
Oncology Fellowship Research Award
UT Southwestern Medical Center (2021)
Seldin Award for Outstanding Intern
UT Southwestern Medical Center (2019)
University Medal for Academic Excellence
Griffith University (2014-2017)

Professional Associations/Affiliations

American Society of Clinical Oncology
International Association for the Study of Lung Cancer